講演情報
[S-42-1]Advancing Translational Research in Guillain-Barré syndrome: Current Treatment and Clinical Trials
Zhahirul Islam1, Mantaka Rahman1, Nowshin Papri1, Imran Hasan1, Israt Jahan1, Shoma Hayat1, Quazi Deen. Mohammad2 (1.Gut-Brain Axis, icddr,b, Dhaka, 2.National Institute of Neurosciences and Hospital, Dhaka, Bangladesh)
Dr. Zhahirul Islam is a Senior Scientist and Head of the Gut-Brain Axis Laboratory at icddr,b. He achieved his Ph.D. from Erasmus University Medical Center, The Netherlands, in collaboration with icddr,b, focusing on Campylobacter infection and Guillain-Barré syndrome (GBS). In 2015-16, he was selected as a Postdoctoral Fellow in the prestigious Global Health Equity Scholars (GHES) program, supported by the NIH, USA, in collaboration with Stanford University, USA and icddr,b. In 2019, Dr. Islam received the Emerging Global Leader Award from the NIH, USA. As a pioneer in GBS research in low- and middle-income countries (LMICs), he has served as the country coordinator (Bangladesh, 2012-) and a steering committee member (2023-) for the International GBS Outcome Study (IGOS). Dr. Islam’s research interests encompass molecular epidemiology, computational biology, cellular immunity, metagenomics, and novel therapeutics for GBS and other autoimmune diseases. His team has developed a cost-effective treatment, Small Volume Plasma Exchange (SVPE), for GBS patients in LMICs. Currently, he is conducting a phase 2/3 clinical trial on a novel monoclonal antibody (C1q inhibitor) for GBS. Additionally, he leads an NIH-funded project to identify biomarkers, nutritional factors, and microbial strain-level differences to predict IVIg treatment response in GBS patients in LMICs.